719brain cancer management , 281–282
cancer therapy ( see Cancer therapy)
cardiogenomics ( see Cardiogenomics)
of epilepsy , 427–428
genetic testing ( see Genetic testing)
Huntington disease , 424
malaria , 406–407
microbial fl ora, leg ulcers , 383–384
MRSA, virulence of , 384–385
translation research , 697
Genomics and Personalized Medicine Act ,
603–604
Genomics and Personalized Medicine
Interagency Working Group , 603
Geriatrics
chronological vs. biological age , 568–569
pharmacogenetics and adverse drug
reactions , 569
Glial cell-derived neurotrophic factor
(GDNF) , 601
Glioblastoma multiforme (GBM) , 212
bioinformatic approach , 279
cancer stem cells , 287
drug resistance , 280
EGFR , 281–283
epigenetic biomarkers , 285
IDH1 genotype and survival , 286
MGMT gene , 286
multigene predictor , 285–286
prognosis of , 283–284
STAT3 in , 281
tumor-initiating cells , 278
Glioma Actively Personalized Vaccine
Consortium (GAPVAC) , 282–283
Global Alliance for Genomics and Health , 643
Glucose sensors , 595
Granulocyte-macrophage colony stimulating
factor (GM-CSF) , 242, 297, 364
GWAS. See Genome-wide association studies
(GWAS)
H
HAART therapy , 394
HapMap Project , 12, 62, 615–616
HBV. See Hepatitis B virus (HBV)
HCV. See Hepatitis C virus (HCV)
Head and neck squamous cell carcinoma
(HNSCC) , 325, 326
Healthcare organizations , 628, 638
Health Information Technology for Economic
and Clinical Health Act
(HITECH) , 638
Hematological malignancies management
acute lymphoblastic leukemia , 327–328
acute myeloid leukemia , 328–330
chronic lymphocytic leukemia , 331–332
MDS , 334
multiple myeloma , 332–333
Hematopoietic cell transplantation (HCT) , 544
Hematopoietic stem cells (HSCs) , 193–194
Hematopoietic stem cell transplant (HSCT) , 405
Hepatitis B virus (HBV) , 401–402
Hepatitis C virus (HCV)
drug resistance , 404
genotype and treatment , 402–404
sequencing role , 404–405
Hepatocellular carcinoma (HCC) , 345, 346
Hepatotoxicity , 125, 166–167
Hereditary nonpolyposis CRC (HNPCC) , 338
High density lipoprotein cholesterol (HDL-C) ,
572, 585–586
High-grade serous cancer (HGSC) , 321, 322
High Impact Clinical Trials , 645
High-risk prostate cancer (HRPC) , 364
Histone methyltransferases (HMTs) , 259
HIV. See Human immunodefi ciency virus (HIV)
Hormone replacement therapy (HRT) , 571–572
Hospital for Sick Children (SickKids) , 628
Host Genetics Core , 390
HSCs. See Hematopoietic stem cells (HSCs)
HudsonAlpha Institute for Biotechnology , 626
β-Human chorionic gonadotrophin (hCG) , 535
Human epidermal growth factor receptor-2
(HER2) , 295–297, 299, 313
Human equilibrative nucleoside transporter-1
(hENT1) , 329, 360
Human genome
CNVs , 11–13
DNA sequencing , 17
ENCODE , 6–7
GENCODE , 6
INDELs , 13–14
large scale variation , 14–15
sequencing, cost of , 683–684
SNPs , 10–11
structural variations , 15–17
Human Genome Epidemiology Network
(HuGENet) , 614
Human immunodefi ciency virus (HIV). See
also Acquired immunodefi ciency
syndrome (AIDS)
anti-HIV drugs , 394
antiretroviral agents , 395
biomarkers role , 397–398
CD4 counts , 397
diagnostic testing , 396–397
drug-resistance , 398–399Index